PPIDT00063

Drug Information
NameBasiliximab
SequenceQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DrugBank_IDDB00074
Typebiotech
IndicationFor prophylactic treatment of kidney transplant rejection

Dosage Forms
Form Route Strength
— Intravenous
20 mg
Injection Intravenous
10 mg
Injection, powder, for solution Intravenous
10 mg
Injection, powder, for solution Intravenous
10 mg/2.5mL
Injection, powder, for solution Intravenous
20 MG
Injection, powder, for solution Intravenous
20 mg/5mL
Injection, powder, for solution Intravenous; Intravenous bolus
20 MG
Powder —
20 mg/1vial
Powder, for solution Intravenous
20 mg / vial
Solution Parenteral
20.00 mg
Injection Intravenous
20 mg
Injection, powder, lyophilized, for solution Intravenous
20 mg
Injection, powder, lyophilized, for solution Intravenous
2000000 mg
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P01589 IL2RA Interleukin-2 receptor subunit alpha Homo sapiens antibody Link
target P14784 IL2RB Interleukin-2 receptor subunit beta Homo sapiens antibody Link